Table of Content

Open Access iconOpen Access

ARTICLE

Evaluation of insulin resistance and plasma levels for visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome

Ozen Oz Gul1, Soner Cander2, Bulent Gul3, Ebru Açıkgoz4, Emre Sarandol4, Canan Ersoy1

1 Uludag University Medical School, Department of Endocrinology and Metabolism, Bursa, Turkey
2 Sevket Yilmaz Education and Reserach Hospital, Department of Endocrinology and Metabolism, Bursa, Turkey
3 Sevket Yilmaz Education and Reserach Hospital, Department of Nephrology, Bursa, Turkey
4 Uludag University Medical School, Department of Biochemistry, Bursa, Turkey

* Corresponding Author: Ozen Oz Gul, email

European Cytokine Network 2015, 26(4), 73-78. https://doi.org/10.1684/ecn.2015.0370

Abstract

This study was designed to evaluate insulin resistance and plasma levels of visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome (PCOS).A total of 37 premenopausal PCOS patients with (n = 18, mean (SD) age: 27.5 (5.7 years) or without obesity (n = 19, mean (SD) age: 23.7 (3.1) years) and healthy volunteers (n = 18, mean (SD) age:29.8 (4.1) years) were included in this study. Data on clinical characteristics, glycemic parameters and lipid parameters were recorded for each subject as were plasma visfatin and resistin levels. Mean (SD) HOMA-IR values were significantly higher in obese PCOS patients (3.4 (1.7)) compared with non-obese PCOS patients (2.0 (1.2), p<0.01) and controls (1.6 (0.8), p<0.01). No significant difference was noted between study groups in terms of plasma resistin (ng/mL) or visfatin (ng/mL) levels. There was no correlation between serum plasma visfatin (r = 0.127, p = 0.407) and resistin (r = -0.096, p = 0.544) levels and HOMA-IR. In conclusion, our findings revealed increased likelihood of metabolic and dyslipidemic manifestations in obese compared to non-obese PCOS patients, while no significant difference was noted in visfatin and resistin levels among PCOS patients in terms of co-morbid obesity and in comparison to controls.

Keywords

polycystic ovary syndrome, insulin resistance, visfatin, resistin, obesity

Cite This Article

APA Style
Gul, O.O., Cander, S., Gul, B., Açıkgoz, E., Sarandol, E. et al. (2015). Evaluation of insulin resistance and plasma levels for visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome. European Cytokine Network, 26(4), 73–78. https://doi.org/10.1684/ecn.2015.0370
Vancouver Style
Gul OO, Cander S, Gul B, Açıkgoz E, Sarandol E, Ersoy C. Evaluation of insulin resistance and plasma levels for visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome. Eur Cytokine Network. 2015;26(4):73–78. https://doi.org/10.1684/ecn.2015.0370
IEEE Style
O.O. Gul, S. Cander, B. Gul, E. Açıkgoz, E. Sarandol, and C. Ersoy, “Evaluation of insulin resistance and plasma levels for visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome,” Eur. Cytokine Network, vol. 26, no. 4, pp. 73–78, 2015. https://doi.org/10.1684/ecn.2015.0370



cc Copyright © 2015 The Author(s). Published by Tech Science Press.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 14

    View

  • 9

    Download

  • 0

    Like

Share Link